2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
6
Recruiting
6
Completed
4
Terminated
2
Withdrawn
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
439
Carboplatin
323
Nivolumab
291
Cyclophosphamide
281
Specimen Handling
271
Magnetic Resonance Spectroscopy
257
Cisplatin
254
Paclitaxel
249
Radiotherapy
229
Gemcitabine
183
Biopsy
182
Dexamethasone
181
durvalumab
169
atezolizumab
151
Rituximab
138
Doxorubicin
135
Lenalidomide
134
Bevacizumab
133
Docetaxel
131
Ipilimumab
129
Capecitabine
120
Radiation
118
Radiosurgery
114
Oxaliplatin
114
Pemetrexed
113
Etoposide
111
Fluorouracil
110
venetoclax
108
fludarabine
106
Prednisone
97
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled